AR094702A1 - Compuestos de azabencimidazol - Google Patents
Compuestos de azabencimidazolInfo
- Publication number
- AR094702A1 AR094702A1 ARP140100515A ARP140100515A AR094702A1 AR 094702 A1 AR094702 A1 AR 094702A1 AR P140100515 A ARP140100515 A AR P140100515A AR P140100515 A ARP140100515 A AR P140100515A AR 094702 A1 AR094702 A1 AR 094702A1
- Authority
- AR
- Argentina
- Prior art keywords
- alkyl
- members
- group
- represented
- optionally substituted
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 title abstract 3
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 abstract 11
- 125000001424 substituent group Chemical group 0.000 abstract 9
- 125000004191 (C1-C6) alkoxy group Chemical group 0.000 abstract 6
- -1 -C (O) NR4R5 Chemical group 0.000 abstract 6
- 125000000217 alkyl group Chemical group 0.000 abstract 6
- 125000004093 cyano group Chemical group *C#N 0.000 abstract 6
- 229910052736 halogen Inorganic materials 0.000 abstract 6
- 125000002887 hydroxy group Chemical group [H]O* 0.000 abstract 6
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 abstract 5
- 150000002367 halogens Chemical class 0.000 abstract 5
- 125000000592 heterocycloalkyl group Chemical group 0.000 abstract 5
- 125000004737 (C1-C6) haloalkoxy group Chemical group 0.000 abstract 4
- 125000000171 (C1-C6) haloalkyl group Chemical group 0.000 abstract 3
- 125000006376 (C3-C10) cycloalkyl group Chemical group 0.000 abstract 3
- 125000000041 C6-C10 aryl group Chemical group 0.000 abstract 3
- 125000004432 carbon atom Chemical group C* 0.000 abstract 3
- 125000001072 heteroaryl group Chemical group 0.000 abstract 3
- 229910052757 nitrogen Inorganic materials 0.000 abstract 3
- 229910052739 hydrogen Inorganic materials 0.000 abstract 2
- 239000001257 hydrogen Substances 0.000 abstract 2
- 125000004435 hydrogen atom Chemical class [H]* 0.000 abstract 2
- 125000005913 (C3-C6) cycloalkyl group Chemical group 0.000 abstract 1
- 208000023275 Autoimmune disease Diseases 0.000 abstract 1
- 208000015114 central nervous system disease Diseases 0.000 abstract 1
- 125000005843 halogen group Chemical group 0.000 abstract 1
- 208000030159 metabolic disease Diseases 0.000 abstract 1
- 230000002503 metabolic effect Effects 0.000 abstract 1
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/14—Decongestants or antiallergics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Immunology (AREA)
- Pulmonology (AREA)
- Psychiatry (AREA)
- Pain & Pain Management (AREA)
- Ophthalmology & Optometry (AREA)
- Diabetes (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Heart & Thoracic Surgery (AREA)
- Hospice & Palliative Care (AREA)
- Cardiology (AREA)
- Rheumatology (AREA)
- Transplantation (AREA)
- Psychology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Epidemiology (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361766268P | 2013-02-19 | 2013-02-19 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR094702A1 true AR094702A1 (es) | 2015-08-19 |
Family
ID=50151342
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP140100515A AR094702A1 (es) | 2013-02-19 | 2014-02-18 | Compuestos de azabencimidazol |
Country Status (30)
| Country | Link |
|---|---|
| US (2) | US9120788B2 (enExample) |
| EP (1) | EP2958915B1 (enExample) |
| JP (2) | JP6505023B2 (enExample) |
| KR (1) | KR20150119370A (enExample) |
| CN (1) | CN105121439A (enExample) |
| AP (1) | AP2015008663A0 (enExample) |
| AR (1) | AR094702A1 (enExample) |
| AU (1) | AU2014220351A1 (enExample) |
| BR (1) | BR112015019276A2 (enExample) |
| CA (1) | CA2900302C (enExample) |
| CL (1) | CL2015002222A1 (enExample) |
| CR (1) | CR20150425A (enExample) |
| CU (1) | CU20150082A7 (enExample) |
| DO (1) | DOP2015000201A (enExample) |
| EA (1) | EA201591360A1 (enExample) |
| EC (1) | ECSP15035278A (enExample) |
| ES (1) | ES2638850T3 (enExample) |
| HK (1) | HK1217945A1 (enExample) |
| IL (1) | IL240672A0 (enExample) |
| MA (1) | MA38333A1 (enExample) |
| MD (1) | MD20150071A2 (enExample) |
| MX (1) | MX2015010714A (enExample) |
| NI (1) | NI201500112A (enExample) |
| PE (1) | PE20151332A1 (enExample) |
| PH (1) | PH12015501755A1 (enExample) |
| SG (1) | SG11201505878UA (enExample) |
| TN (1) | TN2015000347A1 (enExample) |
| TW (1) | TW201443048A (enExample) |
| UY (1) | UY35333A (enExample) |
| WO (1) | WO2014128585A1 (enExample) |
Families Citing this family (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2900302C (en) | 2013-02-19 | 2018-07-03 | Pfizer Inc. | Azabenzimidazole compounds as inhibitors of pde4 isozymes for the treatment of cns and other disorders |
| WO2016012896A1 (en) | 2014-07-24 | 2016-01-28 | Pfizer Inc. | Pyrazolopyrimidine compounds |
| CR20170035A (es) | 2014-08-06 | 2017-04-28 | Pfizer | Compuestos de imidazopiridazina |
| CA2984290C (en) | 2015-04-29 | 2022-03-01 | Janssen Pharmaceutica Nv | Benzimidazolone and benzothiazolone compounds and their use as ampa receptor modulators |
| CN107750250B (zh) | 2015-04-29 | 2021-09-07 | 詹森药业有限公司 | 吲哚酮化合物及其作为ampa受体调节剂的用途 |
| KR20170140382A (ko) * | 2015-04-29 | 2017-12-20 | 얀센 파마슈티카 엔.브이. | 아자벤즈이미다졸 및 ampa 수용체 조절제로서의 이의 용도 |
| BR112017023038A2 (pt) | 2015-04-29 | 2018-07-03 | Janssen Pharmaceutica Nv | imidazopirazinas e pirazolopirimidinas e seu uso como moduladores do receptor ampa |
| BR112017026191B1 (pt) | 2015-06-17 | 2023-10-10 | Pfizer Inc | Compostos tricíclicos inibidores de fosfodiesterase, sua composição farmacêutica e uso dos mesmos |
| AR107099A1 (es) * | 2015-12-22 | 2018-03-21 | Gruenenthal Gmbh | Compuestos espiro-[indolin heterocicloalcano] como inhibidores de la fosfodiesterasa |
| US10323042B2 (en) * | 2016-02-23 | 2019-06-18 | Pfizer Inc. | 6,7-dihydro-5H-pyrazolo[5,1-b][1,3]oxazine-2-carboxamide compounds |
| JP7050054B2 (ja) * | 2016-08-22 | 2022-04-07 | メッドシャイン ディスカバリー インコーポレイテッド | Ｐｄｅ４阻害剤としての縮合環系化合物 |
| WO2018234354A1 (en) | 2017-06-20 | 2018-12-27 | Grünenthal GmbH | Novel substituted 3-indole and 3-indazole compounds as phosphodiesterase inhibitors |
| WO2018234353A1 (en) | 2017-06-20 | 2018-12-27 | Grünenthal GmbH | Novel substituted indole and indazole compounds as phosphodiesterase inhibitors |
| EP3643711A1 (en) | 2018-10-24 | 2020-04-29 | Bayer Animal Health GmbH | New anthelmintic compounds |
| EP3870292A4 (en) | 2018-10-26 | 2022-11-09 | The Research Foundation for The State University of New York | COMBINATION OF SEROTONIN-SPECIFIC RESUPPUT INHIBITOR AND SEROTONIN 1A RECEPTOR PARTIAL AGONIST TO REDUCE L-DOPA-INDUCED DYSKINESIA |
| WO2021095801A1 (ja) | 2019-11-13 | 2021-05-20 | 日本新薬株式会社 | アザベンゾイミダゾール化合物及び医薬 |
| JP7601425B2 (ja) * | 2020-03-31 | 2024-12-17 | エルジー・ケム・リミテッド | 膵島移植保護用組成物 |
| CN112390750B (zh) * | 2020-11-11 | 2022-03-01 | 常州大学 | 作为选择性磷酸二酯酶2抑制剂的喹啉酮类化合物及其制备方法 |
Family Cites Families (138)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5814651A (en) | 1992-12-02 | 1998-09-29 | Pfizer Inc. | Catechol diethers as selective PDEIV inhibitors |
| WO1994017197A1 (fr) | 1993-01-25 | 1994-08-04 | Takeda Chemical Industries, Ltd. | ANTICORPS DIRIGE CONTRE LE β-AMYLOIDE OU UN DERIVE DE CE DERNIER ET SON UTILISATION |
| JPH08295667A (ja) * | 1995-04-27 | 1996-11-12 | Takeda Chem Ind Ltd | 複素環化合物、その製造法および剤 |
| JPH08295687A (ja) * | 1995-04-28 | 1996-11-12 | Ube Ind Ltd | 無水シトラコン酸の製造法 |
| DE19709877A1 (de) | 1997-03-11 | 1998-09-17 | Bayer Ag | 1,5-Dihydro-pyrazolo[3,4-d]-pyrimidinon-derivate |
| CN1177616C (zh) | 1997-04-09 | 2004-12-01 | 曼德塞特生物制药公司 | 特异于β-淀粉状蛋白末端的重组抗体,编码它们的DNA及其使用方法 |
| US8173127B2 (en) | 1997-04-09 | 2012-05-08 | Intellect Neurosciences, Inc. | Specific antibodies to amyloid beta peptide, pharmaceutical compositions and methods of use thereof |
| GB9722520D0 (en) | 1997-10-24 | 1997-12-24 | Pfizer Ltd | Compounds |
| TWI239847B (en) | 1997-12-02 | 2005-09-21 | Elan Pharm Inc | N-terminal fragment of Abeta peptide and an adjuvant for preventing and treating amyloidogenic disease |
| US6905686B1 (en) | 1997-12-02 | 2005-06-14 | Neuralab Limited | Active immunization for treatment of alzheimer's disease |
| CZ27399A3 (cs) | 1999-01-26 | 2000-08-16 | Ústav Experimentální Botaniky Av Čr | Substituované dusíkaté heterocyklické deriváty, způsob jejich přípravy, tyto deriváty pro použití jako léčiva, farmaceutická kompozice a kombinovaný farmaceutický přípravek tyto deriváty obsahující a použití těchto derivátů pro výrobu léčiv |
| BR9916746A (pt) * | 1999-06-03 | 2005-01-11 | Abbott Lab | Compostos anti-inflamatórios que inibem adesão de célula |
| CA2376781A1 (en) | 1999-06-28 | 2001-01-04 | Janssen Pharmaceutica N.V. | Benzimidazoles and imidazopyridines as respiratory syncytial virus replication inhibitors |
| US20030187261A1 (en) | 2000-01-07 | 2003-10-02 | Libor Havlicek | Purine derivatives, process for their preparation and use thereof |
| WO2001062801A2 (en) | 2000-02-24 | 2001-08-30 | Washington University | Humanized antibodies that sequester amyloid beta peptide |
| JP3729343B2 (ja) | 2000-04-27 | 2005-12-21 | アステラス製薬株式会社 | 縮合ヘテロアリール誘導体 |
| DE10045112A1 (de) | 2000-09-11 | 2002-03-21 | Merck Patent Gmbh | Verwendung von Indolderivaten zur Behandlung von Erkrankungen des zentralen Nervensystems |
| AU3976402A (en) | 2000-11-03 | 2002-06-03 | Proteotech Inc | Methods of isolating amyloid-inhibiting compounds and use of compounds isolated from uncaria tomentosa and related plants |
| GB0115181D0 (en) | 2001-06-20 | 2001-08-15 | Glaxo Group Ltd | Novel use |
| WO2003000697A1 (en) | 2001-06-22 | 2003-01-03 | Takeda Chemical Industries, Ltd. | Furoisoquinoline derivative, process for producing the same, and use |
| EP1404330B1 (en) | 2001-06-27 | 2005-06-01 | Merck Frosst Canada & Co. | Substituted 8-arylquinoline pde4 inhibitors |
| EP1405844A4 (en) | 2001-06-29 | 2006-09-20 | Nikken Chemicals Co Ltd | CYCLOALKENONDERIVAT |
| WO2003008396A1 (en) | 2001-07-16 | 2003-01-30 | Nikken Chemicals Co., Ltd. | Optically active oxazine derivative |
| AU2002354850B2 (en) | 2001-07-18 | 2008-02-28 | Merck Patent Gmbh | 4-(benzylidene-amino)-3-(methylsulfanyl)-4H-(1, 2, 4) triazin-5-one derivatives having a PDE-IV inhibiting and TNF-antagonistic effect for the treatment of cardiac diseases and allergies |
| WO2003008373A1 (de) | 2001-07-19 | 2003-01-30 | Merck Patent Gmbh | Tyrosinhydrazide |
| FR2827599A1 (fr) | 2001-07-20 | 2003-01-24 | Neuro3D | Composes derives de quinoleine et quinoxaline,preparation et utilisations |
| GB0118373D0 (en) | 2001-07-27 | 2001-09-19 | Glaxo Group Ltd | Novel therapeutic method |
| TWI221838B (en) | 2001-08-09 | 2004-10-11 | Tanabe Seiyaku Co | Pyrazinoisoquinoline compound or naphthalene compound |
| EP1285922A1 (en) | 2001-08-13 | 2003-02-26 | Warner-Lambert Company | 1-Alkyl or 1-cycloalkyltriazolo[4,3-a]quinazolin-5-ones as phosphodiesterase inhibitors |
| FR2828693B1 (fr) | 2001-08-14 | 2004-06-18 | Exonhit Therapeutics Sa | Nouvelle cible moleculaire de la neurotoxicite |
| CA2456985A1 (en) | 2001-08-15 | 2003-02-27 | Icos Corporation | 2h-phthalazin-1-ones and methods for use thereof |
| AU2002333193A1 (en) | 2001-08-15 | 2003-03-03 | Leo Pharma A/S | A pharmaceutical composition for dermal application |
| WO2003016466A2 (en) | 2001-08-17 | 2003-02-27 | Eli Lilly And Company | ANTI-Aβ ANTIBODIES |
| JO2311B1 (en) | 2001-08-29 | 2005-09-12 | ميرك فروست كندا ليمتد | Alkyl inhibitors Ariel phosphodiesterase-4 |
| GB0122031D0 (en) | 2001-09-12 | 2001-10-31 | Pfizer Ltd | Use of pde4 inhibitors in a dry powder inhaler |
| WO2003024488A2 (en) | 2001-09-19 | 2003-03-27 | Altana Pharma Ag | Combination of a pde inhibitor and a leukotriene receptor antagonist |
| NZ532278A (en) | 2001-09-19 | 2006-02-24 | Altana Pharma Ag | Combination of a PDE inhibitor and an NSAID |
| WO2003035650A1 (en) | 2001-09-25 | 2003-05-01 | Takeda Chemical Industries, Ltd. | Entry inhibitor |
| MXPA04003007A (es) | 2001-10-02 | 2004-07-15 | Upjohn Co | Compuestos azabiciclico sustituidos condensados con heteroarilo para el tratamiento de enfermedades. |
| GB0123951D0 (en) | 2001-10-05 | 2001-11-28 | Glaxo Group Ltd | Therapies for treating respiratory diseases |
| DE10150517A1 (de) | 2001-10-12 | 2003-04-17 | Merck Patent Gmbh | Verwendung von Phosphodiesterase IV-Inhibitoren |
| BR0213660A (pt) | 2001-10-16 | 2004-08-24 | Memory Pharm Corp | Composto, composição farmacêutica e método para tratar pacientes |
| EP2336133A1 (en) | 2001-10-30 | 2011-06-22 | Conforma Therapeutics Corporation | Purine analogs having HSP90-inhibiting activity |
| CZ2004516A3 (cs) | 2001-10-31 | 2004-08-18 | Merckápatentágmbh | Inhibitor fosfodiesterázy typu @Ź jeho kombinace s jinými drogami a jeho použití |
| WO2003037900A2 (en) | 2001-11-01 | 2003-05-08 | Icagen, Inc. | Pyrazolopyrimidines |
| US20030195205A1 (en) | 2001-11-02 | 2003-10-16 | Pfizer Inc. | PDE9 inhibitors for treating cardiovascular disorders |
| MY130622A (en) | 2001-11-05 | 2007-07-31 | Novartis Ag | Naphthyridine derivatives, their preparation and their use as phosphodiesterase isoenzyme 4 (pde4) inhibitors |
| DE60213841T2 (de) | 2001-11-05 | 2007-02-15 | Merck Patent Gmbh | Hydrazono-malonitrile |
| US20030092706A1 (en) | 2001-11-09 | 2003-05-15 | Johannes Barsig | Combination |
| IS7221A (is) | 2001-11-15 | 2004-04-15 | Memory Pharmaceuticals Corporation | Hringlaga adenosínmónófosfat fosfódíesterasa 4D7 ísóform og aðferðir til notkunar þeirra |
| FR2832711B1 (fr) | 2001-11-26 | 2004-01-30 | Warner Lambert Co | Derives de triazolo [4,3-a] pyrido [2,3-d] pyrimidin-5-ones, compositions les contenant, procede de preparation et utilisation |
| US20050101000A1 (en) | 2002-12-11 | 2005-05-12 | Isis Pharmaceuticals Inc. | Modulation of phosphodiesterase 4B expression |
| DE10238724A1 (de) | 2002-08-23 | 2004-03-04 | Bayer Ag | Alkyl-substituierte Pyrazolpyrimidine |
| DE10238723A1 (de) | 2002-08-23 | 2004-03-11 | Bayer Ag | Phenyl-substituierte Pyrazolyprimidine |
| PL377769A1 (pl) | 2002-10-09 | 2006-02-20 | Rinat Neuroscience Corp. | Sposób leczenia choroby Alzheimera z zastosowaniem przeciwciał skierowanych przeciw peptydowi beta amyloidu i ich kompozycje |
| AU2003283303A1 (en) | 2002-11-08 | 2004-06-07 | Bayer Healthcare Ag | Diagnostics and therapeutics for diseases associated with human phosphodiesterase 4b (pde4b) |
| WO2004052315A2 (en) | 2002-12-11 | 2004-06-24 | Merck & Co., Inc. | Tyrosine kinase inhibitors |
| WO2004089471A2 (en) | 2003-04-11 | 2004-10-21 | Novo Nordisk A/S | NEW PYRAZOLO[1,5-a] PYRIMIDINES DERIVATIVES AND PHARMACEUTICAL USE THEREOF |
| ES2338656T3 (es) | 2003-04-11 | 2010-05-11 | High Point Pharmaceuticals, Llc | Uso farmaceutico de 1,2,4-triazoles fusionados. |
| US20040220186A1 (en) | 2003-04-30 | 2004-11-04 | Pfizer Inc. | PDE9 inhibitors for treating type 2 diabetes,metabolic syndrome, and cardiovascular disease |
| US7741341B2 (en) | 2003-05-19 | 2010-06-22 | Sanofi-Aventis Deutschland Gmbh | Benzimidazole-derivatives as factor Xa inhibitors |
| WO2004110996A1 (en) | 2003-06-19 | 2004-12-23 | Pfizer Products Inc. | Nk1 antagonist |
| US20060148805A1 (en) | 2003-07-01 | 2006-07-06 | Meng Hsin Chen | Opthalmic compositions for treating ocular hypertension |
| FR2857966A1 (fr) | 2003-07-24 | 2005-01-28 | Aventis Pharma Sa | Produits aryl-heteroaromatiques, compositions les contenant et utilisation |
| US20050020587A1 (en) | 2003-07-25 | 2005-01-27 | Pfizer Inc | Nicotinamide derivatives useful as PDE4 inhibitors |
| US20070031416A1 (en) | 2003-09-09 | 2007-02-08 | Takeda Pharmaceutical Company Limited | Use of antibody |
| GB0322726D0 (en) | 2003-09-27 | 2003-10-29 | Glaxo Group Ltd | Compounds |
| GB0322722D0 (en) | 2003-09-27 | 2003-10-29 | Glaxo Group Ltd | Compounds |
| CA2539752A1 (en) | 2003-09-29 | 2005-04-07 | Topigen Pharmaceutique Inc. | Oligonucleotide compositions and methods for treating disease including inflammatory conditions |
| GB0327319D0 (en) | 2003-11-24 | 2003-12-24 | Pfizer Ltd | Novel pharmaceuticals |
| WO2005066151A2 (en) | 2003-12-19 | 2005-07-21 | Takeda San Diego, Inc. | Histone deacetylase inhibitors |
| WO2005080361A1 (en) | 2004-02-02 | 2005-09-01 | Pfizer Products Inc. | Histamine-3 receptor modulators |
| CA2565965A1 (en) | 2004-05-06 | 2006-07-27 | Plexxikon, Inc. | Pde4b inhibitors and uses therefor |
| US7456164B2 (en) | 2004-05-07 | 2008-11-25 | Pfizer, Inc | 3- or 4-monosubtituted phenol and thiophenol derivatives useful as H3 ligands |
| EP1595881A1 (en) | 2004-05-12 | 2005-11-16 | Pfizer Limited | Tetrahydronaphthyridine derivates useful as histamine H3 receptor ligands |
| MX2007000998A (es) | 2004-07-30 | 2007-07-11 | Rinat Neuroscience Corp | Anticuerpos dirigidos peptido beta-amiloide y procedimientos que usan los mismos. |
| EP1786813A2 (en) | 2004-09-03 | 2007-05-23 | Plexxikon, Inc. | Bicyclic heteroaryl pde4b inhibitors |
| GB0420719D0 (en) | 2004-09-17 | 2004-10-20 | Addex Pharmaceuticals Sa | Novel allosteric modulators |
| MX2007003329A (es) | 2004-09-20 | 2007-06-05 | Xenon Pharmaceuticals Inc | Derivados heterociclicos y biciclicos y su uso como inhibidores de estearoil-coa-desaturasa (scd). |
| MX2007003342A (es) | 2004-09-21 | 2007-06-05 | Synta Pharmaceutical Corp | Compuestos para inflamacion y usos relacionados con trastornos inmunitarios. |
| FR2877015B1 (fr) | 2004-10-21 | 2007-10-26 | Commissariat Energie Atomique | Revetement nanostructure et procede de revetement. |
| DE102004054634A1 (de) * | 2004-11-12 | 2006-05-18 | Schwarz Pharma Ag | Azaindolcarboxamide |
| EP1827493A4 (en) | 2004-12-22 | 2009-09-30 | Univ St Louis | USE OF ANTI-ABETA ANTIBODIES FOR THE TREATMENT OF BRAIN TRAUMA |
| US20100130737A1 (en) | 2005-02-18 | 2010-05-27 | Takeda Pharmaceutical Company Limited | Regulating Agent of GPR34 Receptor Function |
| GB0503955D0 (en) | 2005-02-25 | 2005-04-06 | Glaxo Group Ltd | Novel compounds |
| PE20061323A1 (es) | 2005-04-29 | 2007-02-09 | Rinat Neuroscience Corp | Anticuerpos dirigidos contra el peptido amiloide beta y metodos que utilizan los mismos |
| EP1881985B1 (en) | 2005-05-12 | 2010-12-29 | Pfizer, Inc. | Anhydrous crystalline forms of n-ý1-(2-ethoxyethyl)-5-(n-ethyl-n-methylamino)-7-(4-methylpyridin-2-yl-amino)-1h-pyrazolo[4,3-d]pyrimidine-3-carbonyl¨methanesulfonamide |
| WO2006126081A2 (en) | 2005-05-24 | 2006-11-30 | Pharmacia & Upjohn Company Llc | Pyridino [2 , 3-b] pyrazinones as pde-5 inhibitors |
| CA2608672A1 (en) | 2005-05-24 | 2006-11-30 | Pharmacia & Upjohn Company Llc | Pyridine [3,4-b] pyrazinones as pde-5 inhibitors |
| WO2006126083A1 (en) | 2005-05-24 | 2006-11-30 | Pharmacia & Upjohn Company Llc | Pyridine [3 , 4-b] pyrazinone compounds as pde-5 inhibitors |
| DE602006018301D1 (de) | 2005-06-22 | 2010-12-30 | Pfizer Prod Inc | Histamin-3-rezeptorantagonisten |
| US8158673B2 (en) | 2005-10-27 | 2012-04-17 | Pfizer Inc. | Histamine-3 receptor antagonists |
| CA2624625A1 (en) | 2005-11-04 | 2007-05-10 | Pfizer Limited | Tetrahydronaphthyridine derivative |
| WO2007063385A2 (en) | 2005-12-01 | 2007-06-07 | Pfizer Products Inc. | Spirocyclic amine histamine-3 receptor antagonists |
| WO2007069053A1 (en) | 2005-12-14 | 2007-06-21 | Pfizer Products Inc. | Benzimidazole antagonists of the h-3 receptor |
| WO2007088462A1 (en) | 2006-02-01 | 2007-08-09 | Pfizer Products Inc. | Spirochromane antagonists of the h-3 receptor |
| WO2007088450A2 (en) | 2006-02-01 | 2007-08-09 | Pfizer Products Inc. | Chromane antagonist of the h-3 receptor |
| WO2007099423A1 (en) | 2006-03-02 | 2007-09-07 | Pfizer Products Inc. | 1-pyrrolidine indane derivatives as histamine-3 receptor antagonists |
| JP2009539762A (ja) | 2006-03-13 | 2009-11-19 | ファイザー・プロダクツ・インク | Ｈ３受容体のテトラリン拮抗薬 |
| GB0605462D0 (en) | 2006-03-17 | 2006-04-26 | Glaxo Group Ltd | Novel compounds |
| CN101454320B (zh) | 2006-04-21 | 2012-12-19 | 辉瑞产品公司 | 吡啶并[3，4-b]吡嗪酮 |
| WO2007138431A2 (en) | 2006-05-30 | 2007-12-06 | Pfizer Products Inc. | Azabicyclic ether histamine-3 antagonists |
| US20080090834A1 (en) | 2006-07-06 | 2008-04-17 | Pfizer Inc | Selective azole pde10a inhibitor compounds |
| KR20090109527A (ko) | 2006-07-07 | 2009-10-20 | 칼립시스, 인코포레이티드 | Ｐｄｅ４의 바이사이클릭 헤테로아릴 억제제 |
| US8138205B2 (en) | 2006-07-07 | 2012-03-20 | Kalypsys, Inc. | Heteroarylalkoxy-substituted quinolone inhibitors of PDE4 |
| RU2450004C2 (ru) | 2006-08-04 | 2012-05-10 | Мерц Фарма Гмбх Унд Ко. Кгаа | Замещенные пиразолопиримидины, способ их получения и их применение в качестве лекарственного средства |
| EP1900739A1 (en) | 2006-08-30 | 2008-03-19 | Cellzome Ag | Diazolodiazine derivatives as kinase inhibitors |
| WO2008033739A2 (en) * | 2006-09-12 | 2008-03-20 | Neurogen Corporation | Benzimidazole carboxamide derivatives |
| WO2008045664A2 (en) | 2006-10-06 | 2008-04-17 | Kalypsys, Inc. | Heterocyclic pde4 inhibitors as antiinflammatory agents |
| WO2008045663A2 (en) | 2006-10-06 | 2008-04-17 | Kalypsys, Inc. | Aryl-substituted heterocyclic pde4 inhibitors as antiinflammatory agents |
| US20080102475A1 (en) | 2006-10-13 | 2008-05-01 | Zhengyan Kan | Alternatively spliced isoform of phosphodiesterase 4B (PDE4B) |
| CL2007002994A1 (es) | 2006-10-19 | 2008-02-08 | Wyeth Corp | Compuestos derivados heterociclicos que contienen sulfamoilo, inhibidores de hsp90; composicion farmaceutica; y uso para el tratamiento del cancer, tal como cancer de mama, de colon y prostata, entre otros. |
| WO2008056176A1 (en) | 2006-11-10 | 2008-05-15 | Scottish Biomedical Limited | Pyrazolopyrimidines as phosphodiesterase inhibitors |
| JP4585610B2 (ja) | 2007-01-22 | 2010-11-24 | ファイザー・プロダクツ・インク | 治療用化合物のトシル酸塩およびその医薬組成物 |
| BRPI0812594A2 (pt) | 2007-08-10 | 2015-06-23 | Lundbeck & Co As H | Composto ou sal ou hidrato do mesmo, composição farmacêutica, métodos para modulação da atividade de um receptor p2x7, para tratamento de uma condição responsiva á modulação do receptor p2x7 em um paciente, para inibição de morte de células gangliônicas retinais em um paciente, para determinação da presença ou ausência de receptor p2x7 em uma amostra, preparação farmacêutica acondicionada, e, uso de um composto ou sal ou hidrato do mesmo. |
| US20090176778A1 (en) | 2007-08-10 | 2009-07-09 | Franz Ulrich Schmitz | Certain nitrogen containing bicyclic chemical entities for treating viral infections |
| EP2085398A1 (en) | 2008-02-01 | 2009-08-05 | Merz Pharma GmbH & Co. KGaA | Pyrazolopyrimidines, a process for their preparation and their use as medicine |
| WO2009108551A2 (en) | 2008-02-25 | 2009-09-03 | H. Lundbeck A/S | Heteroaryl amide analogues |
| GB2461702A (en) | 2008-07-08 | 2010-01-13 | Dyson Technology Ltd | Hand drying apparatus |
| US9643922B2 (en) | 2008-08-18 | 2017-05-09 | Yale University | MIF modulators |
| CN102223798A (zh) | 2008-09-24 | 2011-10-19 | 巴斯夫欧洲公司 | 用于防治无脊椎动物害虫的吡唑化合物 |
| WO2010059836A1 (en) | 2008-11-20 | 2010-05-27 | Decode Genetics Ehf | Substituted aza-bridged bicyclics for cardiovascular and cns disease |
| US20100204265A1 (en) | 2009-02-09 | 2010-08-12 | Genelabs Technologies, Inc. | Certain Nitrogen Containing Bicyclic Chemical Entities for Treating Viral Infections |
| EP2408446B1 (en) | 2009-03-20 | 2019-09-11 | HG&H Pharmaceuticals (Pty) Limited | Use of pharmaceutical compositions containing mesembrenone |
| JP5641664B2 (ja) | 2009-10-30 | 2014-12-17 | ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプＪａｎｓｓｅｎ Ｐｈａｒｍａｃｅｕｔｉｃａ Ｎａａｍｌｏｚｅ Ｖｅｎｎｏｏｔｓｃｈａｐ | イミダゾ［１，２−ｂ］ピリダジン誘導体およびＰＤＥ１０阻害剤としてのそれらの使用 |
| EP2504340A1 (en) | 2009-11-25 | 2012-10-03 | Merz Pharma GmbH & Co. KGaA | Crystalline forms of substituted pyrazolopyrimidines |
| AR079451A1 (es) | 2009-12-18 | 2012-01-25 | Nycomed Gmbh | Compuestos 3,4,4a,10b-tetrahidro-1h-tiopirano[4,3-c]isoquinolina |
| CA2792339A1 (en) | 2010-03-23 | 2011-09-29 | High Point Pharmaceuticals, Llc | Substituted imidazo[1,2-b]pyridazine derivatives, pharmaceutical compositions, and methods of use as beta-secretase inhibitors |
| UY33373A (es) | 2010-05-10 | 2011-12-30 | Gilead Sciences Inc | ?Compuestos de pirazolopiridina bifuncionales, su uso en terapia y composiciones que los comprenden?. |
| JP5807058B2 (ja) | 2010-05-10 | 2015-11-10 | ギリアード サイエンシーズ， インコーポレイテッド | 二機能キノリン誘導体 |
| US8609669B2 (en) | 2010-11-16 | 2013-12-17 | Abbvie Inc. | Potassium channel modulators |
| US9096605B2 (en) | 2011-08-24 | 2015-08-04 | Glaxosmithkline Llc | Pyrazolopyrimidine derivatives as PI3 kinase inhibitors |
| CA2900302C (en) | 2013-02-19 | 2018-07-03 | Pfizer Inc. | Azabenzimidazole compounds as inhibitors of pde4 isozymes for the treatment of cns and other disorders |
| US9193736B2 (en) | 2013-06-11 | 2015-11-24 | Janssen Pharmaceutica, Nv | PDE 10a inhibitors for the treatment of type II diabetes |
| GB201321734D0 (en) | 2013-12-09 | 2014-01-22 | Ucb Pharma Sa | Therapeutic Agents |
| CN111772834B (zh) | 2014-03-21 | 2022-07-15 | 阿莱恩技术有限公司 | 具有弹性体的分段的正畸矫正器 |
| WO2016012896A1 (en) | 2014-07-24 | 2016-01-28 | Pfizer Inc. | Pyrazolopyrimidine compounds |
| CR20170035A (es) | 2014-08-06 | 2017-04-28 | Pfizer | Compuestos de imidazopiridazina |
-
2014
- 2014-02-06 CA CA2900302A patent/CA2900302C/en active Active
- 2014-02-06 JP JP2015557539A patent/JP6505023B2/ja active Active
- 2014-02-06 KR KR1020157025454A patent/KR20150119370A/ko not_active Ceased
- 2014-02-06 PE PE2015001765A patent/PE20151332A1/es not_active Application Discontinuation
- 2014-02-06 EP EP14705882.0A patent/EP2958915B1/en active Active
- 2014-02-06 AU AU2014220351A patent/AU2014220351A1/en not_active Abandoned
- 2014-02-06 MA MA38333A patent/MA38333A1/fr unknown
- 2014-02-06 BR BR112015019276A patent/BR112015019276A2/pt not_active IP Right Cessation
- 2014-02-06 HK HK16105891.1A patent/HK1217945A1/zh unknown
- 2014-02-06 WO PCT/IB2014/058840 patent/WO2014128585A1/en not_active Ceased
- 2014-02-06 ES ES14705882.0T patent/ES2638850T3/es active Active
- 2014-02-06 SG SG11201505878UA patent/SG11201505878UA/en unknown
- 2014-02-06 MD MDA20150071A patent/MD20150071A2/ro not_active Application Discontinuation
- 2014-02-06 CN CN201480009394.5A patent/CN105121439A/zh active Pending
- 2014-02-06 MX MX2015010714A patent/MX2015010714A/es unknown
- 2014-02-06 AP AP2015008663A patent/AP2015008663A0/xx unknown
- 2014-02-06 EA EA201591360A patent/EA201591360A1/ru unknown
- 2014-02-14 US US14/180,463 patent/US9120788B2/en active Active
- 2014-02-18 TW TW103105318A patent/TW201443048A/zh unknown
- 2014-02-18 UY UY0001035333A patent/UY35333A/es not_active Application Discontinuation
- 2014-02-18 AR ARP140100515A patent/AR094702A1/es unknown
-
2015
- 2015-07-21 US US14/804,644 patent/US9815832B2/en not_active Expired - Fee Related
- 2015-08-07 CL CL2015002222A patent/CL2015002222A1/es unknown
- 2015-08-10 PH PH12015501755A patent/PH12015501755A1/en unknown
- 2015-08-11 CU CUP2015000082A patent/CU20150082A7/es unknown
- 2015-08-12 TN TN2015000347A patent/TN2015000347A1/fr unknown
- 2015-08-14 EC ECIEPI201535278A patent/ECSP15035278A/es unknown
- 2015-08-18 IL IL240672A patent/IL240672A0/en unknown
- 2015-08-18 NI NI201500112A patent/NI201500112A/es unknown
- 2015-08-19 CR CR20150425A patent/CR20150425A/es unknown
- 2015-08-19 DO DO2015000201A patent/DOP2015000201A/es unknown
-
2018
- 2018-12-11 JP JP2018231938A patent/JP2019069966A/ja active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR094702A1 (es) | Compuestos de azabencimidazol | |
| AR129635A2 (es) | Moduladores de tetrahidropiridopirazina de gpr6 | |
| AR094299A1 (es) | Derivados de ftalazin-1(2h)-ona sustituidos | |
| AR096684A1 (es) | Compuestos para tratar atrofia muscular espinal | |
| AR100808A1 (es) | Inhibidores de fosfatidilinositol 3-quinasa | |
| AR099379A1 (es) | Compuestos tricíclicos como agentes antineoplásicos | |
| AR100809A1 (es) | Inhibidores de fosfatidilinositol 3-quinasa | |
| AR092349A1 (es) | Imidazotriazincarbonitrilos utiles como inhibidores de quinasa | |
| AR096788A1 (es) | Compuestos tricíclicos de carboxamida como inhibidores potentes de rock | |
| AR107973A1 (es) | 6-hidroxi-4-oxo-1,4-dihidropirimidin-5-carboxamidas como agonista de apj | |
| AR100438A1 (es) | Pirazolopiridinas y pirazolopirimidinas | |
| AR099228A1 (es) | Inhibidores macrocíclicos de fxia que tienen grupos heterocíclicos | |
| AR103833A1 (es) | Compuestos bicíclicos de sulfonamida cetona | |
| AR100807A1 (es) | Inhibidores de fosfatidilinositol 3-quinasa | |
| AR088449A1 (es) | Benzilindazoles sustituidos | |
| AR100975A1 (es) | Inhibidores de fosfatidilinositol 3-quinasa | |
| AR092809A1 (es) | 3,5-diaminopirazol como inhibidor de quinasa | |
| AR107042A1 (es) | Inhibidores de la tirosina quinasa de bruton y métodos de su uso | |
| AR103742A1 (es) | Derivados de trifluorometilpropanamida | |
| AR095708A1 (es) | Indazoles sustituidos con diaminoheteroarilo | |
| AR108864A1 (es) | Agentes antibacterianos | |
| AR093758A1 (es) | Inhibidores de aril lactama quinasa | |
| AR096161A1 (es) | Derivados de triazina | |
| AR110440A1 (es) | Compuestos para el tratamiento de la enfermedad respiratoria bovina o porcina | |
| AR104293A1 (es) | Indazolonas como moduladores de la señalización de tnf |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FB | Suspension of granting procedure |